Fundraising Fox

Biohaven Pharmaceuticals

4 known investors

Biohaven is a biopharmaceutical company that discovers, develops, and commercializes treatments across immunology, obesity, neuroscience, and oncology, targeting rare and common diseases with limited treatment options. Its commercialized products include migraine therapies, and it advances a portfolio of early- to late-stage drug development programs.

BiotechHealthtech

Founders & leadership

VCVlad Coric
Vlad CoricChairman & Chief Executive Officer

Investors · 4

Aisling CapitalNew York
APERTURE Venture PartnersBoston · $1M – $5M
Connecticut InnovationsNew Haven · $500K – $2M
OUP (Osage University Partners)Bala Cynwyd · $1M – $20M

In the news

Biohaven reduces scope of R&D cutbacks as pipeline progressesfiercebiotech.com · Mar 2026RBC Capital raises Biohaven Pharma stock price target on model tweaks By Investing.cominvesting.com · Mar 2026BioShin, Biohaven's Asia-Pacific Subsidiary, Raises $60M in Series A Funding to Advance Neuroscience Pipeline in Asia-Pacific Regionprnewswire.com · Sep 2020

Frequently asked questions

What does Biohaven Pharmaceuticals do?
Biohaven is a biopharmaceutical company that discovers, develops, and commercializes treatments across immunology, obesity, neuroscience, and oncology, targeting rare and common diseases with limited treatment options. Its commercialized products include migraine therapies, and it advances a portfolio of early- to late-stage drug development programs.
Who are Biohaven Pharmaceuticals's investors?
Biohaven Pharmaceuticals's investors include Aisling Capital, APERTURE Venture Partners, Connecticut Innovations, OUP (Osage University Partners).